Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) Return on Invested Capital (2020)

Historic Return on Invested Capital for Denali Therapeutics (DNLI) over the last 5 years, with Q4 2023 value amounting to 0.18%.

  • Denali Therapeutics' Return on Invested Capital rose 1800.0% to 0.18% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.18%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 0.43% for FY2024, which is 2400.0% down from last year.
  • Latest data reveals that Denali Therapeutics reported Return on Invested Capital of 0.18% as of Q4 2023, which was up 1800.0% from 0.15% recorded in Q3 2023.
  • Denali Therapeutics' Return on Invested Capital's 5-year high stood at 0.06% during Q4 2020, with a 5-year trough of 0.51% in Q4 2019.
  • In the last 5 years, Denali Therapeutics' Return on Invested Capital had a median value of 0.18% in 2023 and averaged 0.22%.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first soared by 5700bps in 2020, then tumbled by -3900bps in 2022.
  • Over the past 5 years, Denali Therapeutics' Return on Invested Capital (Quarter) stood at 0.51% in 2019, then skyrocketed by 112bps to 0.06% in 2020, then tumbled by -590bps to 0.3% in 2021, then decreased by -22bps to 0.37% in 2022, then skyrocketed by 50bps to 0.18% in 2023.
  • Its last three reported values are 0.18% in Q4 2023, 0.15% for Q3 2023, and 0.15% during Q2 2023.